GlassScriptPhysician profile
Scott L Kramer
NPI 1043273295
$3,729.27
in general payments reported to CMS, 2019-2025
22 companies · $900 in 2025
The $900 reported for 2025 was more than what 83% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $681 · 2021: $447 · 2022: $543 · 2023: $617 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $900 · Food and Beverage: $544 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $900.00 |
| Food and Beverage | $544.42 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $900.00 | 2025 | |
| Abbvie INC. | $643.95 | 2019-2023 | |
| Therapeuticsmd, INC. | $572.96 | 2019-2022 | |
| Aegea Medical, INC. | $485.00 | 2020 | |
| Astellas Pharma US INC | $214.89 | 2022-2023 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $162.97 | 2023 | |
| Myovant Sciences INC. | $134.74 | 2021-2022 | |
| Boston Scientific Corporation | $123.34 | 2019 | |
| Myriad Women'S Health, INC. | $112.74 | 2023 | Myrisk |
| Akcea Therapeutics, INC. | $55.21 | 2019 | |
| Amgen INC. | $44.12 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $43.36 | 2023 | Myfembree |
| Amarin Pharma, INC. | $39.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.26 | 2019-2021 | |
| Lilly USA, LLC | $29.71 | 2023 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.50 | 2022 | |
| Minerva Surgical, INC | $24.39 | 2023 | |
| Janssen Pharmaceuticals, INC | $19.69 | 2019 | |
| Aspira Women'S Health INC | $17.49 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.30 | 2020 | |
| Evofem Biosciences, INC. | $16.79 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.